For most health plans, self-funded employers, and Taft-Hartley funds, the fall review cycle follows a predictable structure. Benefit design gets assessed against ACA compliance thresholds. Open enrollment communications get finalized. Stop-loss terms get evaluated. TPA performance gets reviewed: claims turnaround, reporting quality, cost containment results. PBM contracts get examined for the coming plan year.
These are the right questions. They also represent the same agenda, reliably, every year.
One question that doesn’t make the standard list: whether the current TPA relationship includes any process for pursuing manufacturer rebates on specialty drugs billed through the medical benefit.
The National Alliance of Healthcare Purchaser Coalitions found this year that 60% of employers are already reviewing pharmacy claims billed through the medical benefit. The channel is on the radar. What happens after the review- specifically, whether anyone is structured to pursue the manufacturer rebates available on those claims- is where the gap opens.
PSG’s 2026 Trends in Specialty Drug Benefits Report documented the result: 93% of employers receive specialty drug rebates under the pharmacy benefit. Under the medical benefit, 43% do. The 50-point gap between those two numbers persists across plan types and fund sizes. And when PSG asked employers not receiving medical benefit rebates why, 29% said the question had simply never been raised with their health plan or TPA.
That 29% is the population most directly affected by what gets added, or doesn’t get added, to the Q4 vendor review agenda.
The standard TPA evaluation covers what’s visible. Published evaluation frameworks for self-funded employer TPA reviews, including Boon-Chapman’s widely referenced guide on TPA performance assessment, focus on claims data access, medical management, reporting capabilities, network depth, compliance support, and cost containment programs. These are the right areas to evaluate.
Medical benefit rebate management doesn’t appear in structured TPA evaluation guides. It isn’t a standard line item in benefit design reviews. It rarely surfaces in open enrollment planning conversations. The reason isn’t that it doesn’t matter; it’s that the infrastructure to ask about it hasn’t been built into the annual review cycle the way pharmacy benefit evaluation has.
Physician-administered specialty drugs are billed as medical claims through the TPA, not the PBM. The manufacturer rebate programs on those drugs, where they exist, are governed by the TPA agreement, not the pharmacy contract. Whether a TPA relationship includes a process to identify and pursue those rebates is a contract and scope question, not a clinical one. It belongs in the vendor review. It typically isn’t there.
Q4 matters for a specific reason: decisions made in this window determine what’s in place for the benefit year. A gap identified in October can be addressed before January. A gap that doesn’t get identified in October waits for the following cycle.
For advisors and consultants working through Q4 reviews with self-funded clients right now, this is a concrete addition to the evaluation checklist: one question, scoped to medical benefit administration, with a clear answer either way. For plan sponsors reviewing TPA contracts before renewal: the question of whether the current agreement addresses medical benefit specialty drug rebates has a yes or no answer that’s worth knowing.
For trustees of Taft-Hartley funds with ERISA fiduciary obligations: service provider oversight is part of the fiduciary duty. Whether the fund’s TPA is structured to pursue available manufacturer rebates on medical benefit specialty drug claims is a monitoring question that fits squarely within that obligation.
The question to add: Does our current TPA agreement include a process for identifying and pursuing manufacturer rebates on specialty drugs billed through the medical benefit, and if not, what would that require?
It takes a few minutes to ask. The answer, in most cases, hasn’t been documented.
Whether you’re heading into a TPA review, open enrollment planning, or a Q4 board meeting, has the medical benefit rebate question made it onto the agenda this year? Comment below.
Disclaimer: This newsletter references publicly available findings from Pharmaceutical Strategies Group’s 2026 Trends in Specialty Drug Benefits Report, the National Alliance of Healthcare Purchaser Coalitions’ 2026 Pulse of the Purchaser Survey, and publicly available vendor evaluation resources. VativoRx is not affiliated with, endorsed by, or partnered with any organization referenced. This newsletter is provided for informational and educational purposes only and does not constitute legal, regulatory, fiduciary, or financial advice. Plan sponsors and trustees should consult qualified ERISA counsel and benefit advisors regarding their specific obligations and vendor agreements.